PE20242078A1 - Una combinacion que comprende un inhibidor de hdac6 especifico y al menos un inhibidor del punto de control de ctla4 - Google Patents

Una combinacion que comprende un inhibidor de hdac6 especifico y al menos un inhibidor del punto de control de ctla4

Info

Publication number
PE20242078A1
PE20242078A1 PE2023002749A PE2023002749A PE20242078A1 PE 20242078 A1 PE20242078 A1 PE 20242078A1 PE 2023002749 A PE2023002749 A PE 2023002749A PE 2023002749 A PE2023002749 A PE 2023002749A PE 20242078 A1 PE20242078 A1 PE 20242078A1
Authority
PE
Peru
Prior art keywords
inhibitor
combination
checkpoint inhibitor
ctla4 checkpoint
ctla4
Prior art date
Application number
PE2023002749A
Other languages
English (en)
Spanish (es)
Inventor
Gianluca Fossati
Flavio Leoni
Pietro Samuele Pozzi
Elisabetta Galbiati
Christian Steinkuhler
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of PE20242078A1 publication Critical patent/PE20242078A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2023002749A 2021-04-20 2022-04-19 Una combinacion que comprende un inhibidor de hdac6 especifico y al menos un inhibidor del punto de control de ctla4 PE20242078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (1)

Publication Number Publication Date
PE20242078A1 true PE20242078A1 (es) 2024-10-18

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002749A PE20242078A1 (es) 2021-04-20 2022-04-19 Una combinacion que comprende un inhibidor de hdac6 especifico y al menos un inhibidor del punto de control de ctla4

Country Status (17)

Country Link
US (1) US20240207228A1 (https=)
EP (1) EP4326259A1 (https=)
JP (1) JP2024515100A (https=)
KR (1) KR20230172001A (https=)
CN (1) CN117177745A (https=)
AR (1) AR125356A1 (https=)
AU (1) AU2022262199A1 (https=)
BR (1) BR112023021125A2 (https=)
CA (1) CA3213275A1 (https=)
CL (1) CL2023002894A1 (https=)
CO (1) CO2023013780A2 (https=)
IL (1) IL307649A (https=)
IT (1) IT202100009926A1 (https=)
MX (1) MX2023012030A (https=)
PE (1) PE20242078A1 (https=)
TW (1) TW202308609A (https=)
WO (1) WO2022223543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008346A (es) * 2016-01-11 2019-07-04 Turnstone Lp Terapia de combinación de virus oncológico e inhibidor de punto de control.
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Also Published As

Publication number Publication date
BR112023021125A2 (pt) 2023-12-12
EP4326259A1 (en) 2024-02-28
WO2022223543A1 (en) 2022-10-27
AU2022262199A1 (en) 2023-09-21
US20240207228A1 (en) 2024-06-27
CL2023002894A1 (es) 2024-03-15
JP2024515100A (ja) 2024-04-04
AR125356A1 (es) 2023-07-12
TW202308609A (zh) 2023-03-01
KR20230172001A (ko) 2023-12-21
IT202100009926A1 (it) 2022-10-20
IL307649A (en) 2023-12-01
CO2023013780A2 (es) 2023-11-10
CN117177745A (zh) 2023-12-05
MX2023012030A (es) 2023-10-24
CA3213275A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2021010544A (es) Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
CL2019001842A1 (es) Nuevos derivados de fenilo.
MX2021010951A (es) Composición líquida que comprende un anticuerpo del receptor alfa de interleucina-4 humano.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX383499B (es) Agentes terapeuticos para enfermedades neurodegenerativas
UA118149C2 (uk) Інгібітор jak
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX373363B (es) Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
CO2022000426A2 (es) Inhibidores de calicreína plasmática
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
ECSP19016844A (es) Combinación de agonistas de fxr
PE20242078A1 (es) Una combinacion que comprende un inhibidor de hdac6 especifico y al menos un inhibidor del punto de control de ctla4
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
CL2013000492A1 (es) Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de peso
CL2020000219A1 (es) Agente terapéutico para fibrosis.
MX2020004250A (es) Composicion farmaceutica de liberacion sostenida.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CO2021003412A2 (es) Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables